Inozyme Pharma Inc expected to post a loss of 82  cents a share - Earnings Preview

Inozyme Pharma

06/05/2022 19:32

* Inozyme Pharma Inc  INZY.OQ   INZY.O  is expected to show
no
change in quarterly revenue when it reports  results on May 10
(estimated). 
    * ​Refinitiv's mean analyst estimate for Inozyme Pharma Inc
is for
a loss of 82 cents per share. For the same quarter last year,
the company reported a loss of 47 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Inozyme
Pharma
Inc is $26​, above​ its last closing price of $3.78. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.72       -0.68      -0.79     Missed  -15.3
 Sep. 30 2021  -0.60       -0.61      -0.60     Beat    1.7
 Jun. 30 2021  -0.57       -0.57      -0.53     Beat    7​
 Mar. 31 2021  -0.54       -0.54      -0.47     Beat    13.2
 ​​Dec.                    -0.55      -1.01     Missed  -85
 31 2020                                                
 Sep. 30 2020  -0.51       -0.51      -1.55     Missed  -203.9
                                                        ​
 Jun. 30 2020  -1.41       -1.41      -7.57     Missed  -435.9
 This summary was machine generated May 6 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated